Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus XR vs Immediate-Release Tacrolimus in Sensitized Kidney Transplant
NCT04225988Phase 4Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jan 2020
- Primary completion
- Jul 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Number of Participants With Biopsy-proven Acute Rejection at 12 months. Started Jan 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04225988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225988.